The overall objective of this contract is to provide NIDA with safety pharmacology & toxicology testing services for novel compounds being developed for the treatment of substance use disorders. SRI will perform pharmacology, safety, & toxicity studies to support Investigational New Drug and New Drug Application submissions to the U.S. FDA on compounds identified by the NIDA COR for inclusion in this program. The exact details of the work to be conducted for individual compounds or tasks will be determined on a case-by-case basis, as directed by the NIDA COR.